Adoption of triplet therapy and clinical outcomes in routine practice among newly diagnosed multiple myeloma patients not receiving frontline stem cell transplant in the USA
Sign Up to like & getrecommendations! Published in 2019 at "Expert Review of Hematology"
DOI: 10.1080/17474086.2019.1555460
Abstract: ABSTRACT Background: Immunomodulator (IMID) and proteasome inhibitor (PI) triplet frontline therapy (FT) in newly diagnosed multiple myeloma (NDMM) trials improve overall survival (OS); reported outcomes in routine practice are lacking. Authors compared outcomes in NDMM… read more here.
Keywords: newly diagnosed; imid triplet; triplet; multiple myeloma ... See more keywords